$THC

KERREY J ROBERT sold $294K of THC

KERREY J ROBERT sold 1,690 shares of TENET HEALTHCARE CORP (THC) at $173.97 ($0.29M total) on 2026-05-28.

Original reporting
SEC EDGAR · KERREY J ROBERT
Published May 30, 2026, 12:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 30, 2026, 12:01 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$THC
Bearish
medium confidence
Mentioned
$THC
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$THCBearishLow
01

Why it matters

This disclosure may modestly affect short-term sentiment toward Tenet Healthcare, but it does not provide new company performance or outlook information.

02

Market read

A director’s open-market sale worth ~$294K is a small, sentiment-oriented datapoint for THC.

03

What to watch

Insider sales can be scheduled for tax/financial planning, and the absence of a stated 10b5-1 plan does not confirm opportunistic trading or negative fundamentals.

Relevance 6/10Novelty 6/10Timing: Filed 2026-05-29 for a sale executed 2026-05-28

Background

SEC Form 4 discloses insider transactions by directors/officers/10% owners; these are typically monitored for sentiment but are not equivalent to earnings or guidance changes.

Company-level read

Ticker impact

$THCBearishMedium confidence
Context

Tenet Healthcare director KERREY J ROBERT sold 1,690 shares in an open-market transaction worth about $294K, disclosed via SEC Form 4.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven and small unless followed by additional insider selling or company-specific news.

Evidence & confidence

Form 4 insider sales are common and often non-informational; however, the director’s sale can slightly increase perceived risk, especially because the filing notes no pre-arranged 10b5-1 plan.

Market effects

Minimal—single-company insider transaction with no stated sector-wide development.

None indicated.

None indicated.

Counterpoint

The sale could be routine liquidity/portfolio rebalancing; without evidence of broader selling or operational issues, price impact may be negligible.

Key entities

  • Tenet Healthcare Corp

    Subject of the insider sale disclosure; director sold 1,690 shares at ~$173.97 on 2026-05-28.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$THCMedAI 8/10

What Tenet Healthcare (THC)'s $2b Debt Refinance Means For Shareholders

Tenet Healthcare (THC) priced a $2.0 billion private placement of 6.250% senior notes due 2034, upsized from $1.5 billion, to refinance existing 2027 and 2028 debt. The refinancing replaces secured and partly secured borrowings with unsecured notes, altering the company's debt structure. Investors focus on execution, pricing, and free cash flow, with high debt and earnings declines noted as risks.

$THCMedAI 8/10

Tenet Healthcare at Wells Fargo conference: high-acuity push deepens

Tenet Healthcare (THC) presented at the Wells Fargo Healthcare Conference, outlining a strategy focused on high-acuity care, capital spending, and cost control. The company raised full-year guidance, citing volume growth and cost discipline. Shares are near their 52-week high at $268.82, up over 30% year-to-date. Tenet expects continued pressure in some payer channels and near-term earnings drag from Conifer's transition. Management plans to invest in complex procedures and maintain capital spen